Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Original

Effect of inhaled corticosteroid with oral montelukast and levocetirizine in asthma: A population-based study 

Myunghee Park, Seong-Dae Woo, Minae Park, Yujin Lee, and Hwa Jeong Seo

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 64 (2026) p. 210 - 218

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 64 – No. 4/2026 (210-218)

Effect of inhaled corticosteroid with oral montelukast and levocetirizine in asthma: A population-based study 

Myunghee Park¹#², Seong-Dae Woo³, Minae Park¹, Yujin Lee¹, and Hwa Jeong Seo²

¹Department of Data Science, Hanmi Pharm Co Ltd, Seoul, Republic of Korea, ²Medical informatics and health Technology (MiT), Department of Medical Industry Management, College of Business, Gachon University, Seongnam, and ³Department of Pulmonary, Allergy, and Critical Care Medicine, Chungnam National University School of Medicine, Daejeon, South Korea
Introduction: Asthma is a chronic disease that requires careful management, and its exacerbations can be life-threatening. The aim of this study was to ascertain whether inhaled corticosteroids (ICS)-containing inhaler in combination with oral montelukast and levocetirizine could lessen the exacerbation of asthma in comparison to inhaler alone.
Materials and methods: Among 437,915 asthma patients receiving ICS-containing inhaler, 91,122 participants were included. Treatment groups were categorized as (1) ICS-containing inhalers (ICS with or without long-acting β-2 agonist (LABA)), and (2) ICS-containing inhalers used in combination with both oral montelukast and levocetirizine, and (3) severe exacerbation of asthma (visit of emergency room or hospitalization). After 1 : 1 propensity score matching of treatment groups, survival analysis utilizing Cox regression was conducted for estimating the effect of treatment on asthma exacerbation.
Results: We found that the inhaler plus montelukast and levocetirizine group exhibited a lower crude incidence rate and was associated with a lower risk of all-cause death and moderate to severe exacerbation. Specifically, the adjusted hazard ratios (HRs) were 0.71 (p = 0.006) for all-cause death, 0.57 (p < 0.001) for moderate exacerbation. For severe exacerbations, the adjusted HRs were 0.59 for emergency room visits and 0.66 for hospitalizations (p = 0.018 and 0.011, respectively), compared to the ICS-only group, demonstrating a statistically significant reduction.
Conclusion: Treatment with ICS-containing inhaler plus oral montelukast and levocetirizine was significantly associated with a lower risk of exacerbations in asthma patients. Alongside the growing burden of healthcare utilization and costs in South Korea, consideration of the treatment of ICS with montelukast and levocetirizine may serve as an effective treatment option for patients with severe, uncontrolled asthma, potentially improving disease management and reducing healthcare costs.Correspondence to:
Hwa Jeong Seo, PhD
Medical informatics and health Technology (MiT)
Department of Medical Industry Management
Gachon University
1342 Seongnamdaero, Sujeong-gu,
Seongnam 13120, Gyeinggi-do, South Korea
Email: [email protected]

Shopping Overview

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail